Video yükleniyor...

Video Yüklenemedi

Bu video yüklenirken bir sorun oluştu. Bu geçici bir ağ sorunundan kaynaklanıyor olabilir veya video kullanılamıyor olabilir.

Ana Sayfaya Dön

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗮𝘄𝗮𝘆 𝗸𝗶𝘁𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝟮𝟬𝟮𝟯/𝟮𝟰 𝗰𝗮𝗺𝗽𝗮𝗶𝗴𝗻. 👕 #AlbionFamily | #WBA

West Bromwich Albion

1,079,183 subscribers

146,054 görüntüleme • 3 yıl önce •via X (Twitter)

#AlbionFamily #WBA

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝟮𝟬𝟮𝟯/𝟮𝟰 𝗚𝗼𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗦𝗲𝗮𝘀𝗼𝗻 𝗪𝗶𝗻𝗻𝗲𝗿... Jimmy Muitt vs Hartlepool on the final day 😮‍💨 Stay tuned for a chance to win the match ball 👀

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝟮𝟬𝟮𝟯/𝟮𝟰 𝗚𝗼𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗦𝗲𝗮𝘀𝗼𝗻 𝗪𝗶𝗻𝗻𝗲𝗿... Jimmy Muitt vs Hartlepool on the final day 😮‍💨 Stay tuned for a chance to win the match ball 👀

Dorking Wanderers FC

44,732 görüntüleme • 2 yıl önce

𝗧𝗵𝗼𝗺𝗮𝘀 𝗪𝗮𝗹𝗸𝘂𝗽 𝗶𝘀 𝘁𝗵𝗲 𝟮𝟬𝟮𝟯-𝟮𝟰 𝗘𝘂𝗿𝗼𝗟𝗲𝗮𝗴𝘂𝗲 𝗕𝗲𝘀𝘁 𝗗𝗲𝗳𝗲𝗻𝗱𝗲𝗿 🏆 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗻 𝗮𝗻 𝗶𝗻𝗰𝗿𝗲𝗱𝗶𝗯𝗹𝗲 𝘀𝗲𝗮𝘀𝗼𝗻 - 𝘀𝗲𝗲 𝘆𝗼𝘂 𝗶𝗻 𝗕𝗲𝗿𝗹𝗶𝗻 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 😉

𝗧𝗵𝗼𝗺𝗮𝘀 𝗪𝗮𝗹𝗸𝘂𝗽 𝗶𝘀 𝘁𝗵𝗲 𝟮𝟬𝟮𝟯-𝟮𝟰 𝗘𝘂𝗿𝗼𝗟𝗲𝗮𝗴𝘂𝗲 𝗕𝗲𝘀𝘁 𝗗𝗲𝗳𝗲𝗻𝗱𝗲𝗿 🏆 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗻 𝗮𝗻 𝗶𝗻𝗰𝗿𝗲𝗱𝗶𝗯𝗹𝗲 𝘀𝗲𝗮𝘀𝗼𝗻 - 𝘀𝗲𝗲 𝘆𝗼𝘂 𝗶𝗻 𝗕𝗲𝗿𝗹𝗶𝗻 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 😉

EuroLeague

242,358 görüntüleme • 2 yıl önce

🇸🇴🇵🇸𝗔𝘀 𝗮 𝗦𝗼𝗺𝗮𝗹𝗶 𝗰𝗶𝘁𝗶𝘇𝗲𝗻, 𝘆𝗼𝘂𝗿 𝗲𝘆𝗲𝘀 𝘄𝗶𝗹𝗹 𝗳𝗶𝗹𝗹 𝘄𝗶𝘁𝗵 𝘁𝗲𝗮𝗿𝘀 𝗯𝗲𝗰𝗮𝘂𝘀𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗹𝗼𝘃𝗲 𝘆𝗼𝘂 𝗵𝗮𝘃𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗣𝗮𝗹𝗲𝘀𝘁𝗶𝗻𝗶𝗮𝗻𝘀. بصفتك مواطنًا صوماليًا، ستغمر عيناك الدموع بسبب الحب الذي تحمله للفلسطينيين. #Palestinian #Somalia

🇸🇴🇵🇸𝗔𝘀 𝗮 𝗦𝗼𝗺𝗮𝗹𝗶 𝗰𝗶𝘁𝗶𝘇𝗲𝗻, 𝘆𝗼𝘂𝗿 𝗲𝘆𝗲𝘀 𝘄𝗶𝗹𝗹 𝗳𝗶𝗹𝗹 𝘄𝗶𝘁𝗵 𝘁𝗲𝗮𝗿𝘀 𝗯𝗲𝗰𝗮𝘂𝘀𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗹𝗼𝘃𝗲 𝘆𝗼𝘂 𝗵𝗮𝘃𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗣𝗮𝗹𝗲𝘀𝘁𝗶𝗻𝗶𝗮𝗻𝘀. بصفتك مواطنًا صوماليًا، ستغمر عيناك الدموع بسبب الحب الذي تحمله للفلسطينيين. #Palestinian #Somalia

Abdikarin Dahir 🇸🇴I🇬🇧

28,527 görüntüleme • 1 yıl önce

💵 Thousands looted by Consultants, 💰 Millions pocketed by the Government. 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝘀𝗰𝗮𝗹𝗲 — 𝗦𝗮𝗺𝗲 𝘀𝗰𝗮𝗺. So tell me — 𝘄𝗵𝗼’𝘀 𝘁𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝗿 𝗦𝗰𝘂𝗺𝗯𝗮𝗴? ImmigrantON took the money and delivered nothing. 𝗡𝗼 𝗷𝘂𝘀𝘁𝗶𝗰𝗲 𝗳𝗼𝗿 𝗢𝗻𝘁𝗮𝗿𝗶𝗼’𝘀 𝟮𝟬𝟮𝟯 & 𝟮𝟬𝟮𝟰 𝗣𝗡𝗣 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝗻𝘁𝘀.

💵 Thousands looted by Consultants, 💰 Millions pocketed by the Government. 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝘀𝗰𝗮𝗹𝗲 — 𝗦𝗮𝗺𝗲 𝘀𝗰𝗮𝗺. So tell me — 𝘄𝗵𝗼’𝘀 𝘁𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝗿 𝗦𝗰𝘂𝗺𝗯𝗮𝗴? ImmigrantON took the money and delivered nothing. 𝗡𝗼 𝗷𝘂𝘀𝘁𝗶𝗰𝗲 𝗳𝗼𝗿 𝗢𝗻𝘁𝗮𝗿𝗶𝗼’𝘀 𝟮𝟬𝟮𝟯 & 𝟮𝟬𝟮𝟰 𝗣𝗡𝗣 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝗻𝘁𝘀.

Kanwar Sierah, RCIC

13,442 görüntüleme • 11 ay önce

[Eng Sub] One day in New York with Lingling Kwong. ⚠️ 𝗡𝗢𝗧𝗜𝗖𝗘 𝗧𝗢 𝗖𝗢𝗡𝗧𝗘𝗡𝗧 𝗧𝗛𝗜𝗘𝗩𝗘𝗦 "𝘛𝘰 𝘸𝘩𝘰𝘦𝘷𝘦𝘳 𝘴𝘵𝘦𝘢𝘭𝘴, 𝘮𝘰𝘥𝘪𝘧𝘪𝘦𝘴, 𝘦𝘥𝘪𝘵𝘴, 𝘰𝘳 𝘶𝘴𝘦𝘴 𝘵𝘩𝘪𝘴 𝘵𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘵𝘩𝘦𝘪𝘳 𝘰𝘸𝘯 𝘣𝘦𝘯𝘦𝘧𝘪𝘵 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 𝘱𝘳𝘰𝘱𝘦𝘳 𝘤𝘳𝘦𝘥𝘪𝘵: 𝗠𝗮𝘆 𝘆𝗼𝘂 𝗴𝗲𝘁 𝘀𝘂𝗲𝗱 𝗳𝗼𝗿 𝗰𝗼𝗽𝘆𝗿𝗶𝗴𝗵𝘁 𝗶𝗻𝗳𝗿𝗶𝗻𝗴𝗲𝗺𝗲𝗻𝘁 𝘂𝗻𝘁𝗶𝗹 𝘆𝗼𝘂'𝗿𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗹𝘆 𝗯𝗿𝗼𝗸𝗲, 𝗮𝗹𝗹 𝘆𝗼𝘂𝗿 𝗮𝗰𝗰𝗼𝘂𝗻𝘁𝘀 𝗴𝗲𝘁 𝘀𝗵𝗮𝗱𝗼𝘄𝗯𝗮𝗻𝗻𝗲𝗱 𝗮𝗻𝗱 𝘀𝘂𝘀𝗽𝗲𝗻𝗱𝗲𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗿𝗲𝘀𝘁 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗹𝗶𝗳𝗲." LINGLING APAC FACE OF CK #CalvinKleinSS27xLINGLING #LinglingkwongxCalvinklein #CalvinKleinSS27 #NYFW #CalvinKlein #LinglingKwong

[Eng Sub] One day in New York with Lingling Kwong. ⚠️ 𝗡𝗢𝗧𝗜𝗖𝗘 𝗧𝗢 𝗖𝗢𝗡𝗧𝗘𝗡𝗧 𝗧𝗛𝗜𝗘𝗩𝗘𝗦 "𝘛𝘰 𝘸𝘩𝘰𝘦𝘷𝘦𝘳 𝘴𝘵𝘦𝘢𝘭𝘴, 𝘮𝘰𝘥𝘪𝘧𝘪𝘦𝘴, 𝘦𝘥𝘪𝘵𝘴, 𝘰𝘳 𝘶𝘴𝘦𝘴 𝘵𝘩𝘪𝘴 𝘵𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘵𝘩𝘦𝘪𝘳 𝘰𝘸𝘯 𝘣𝘦𝘯𝘦𝘧𝘪𝘵 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 𝘱𝘳𝘰𝘱𝘦𝘳 𝘤𝘳𝘦𝘥𝘪𝘵: 𝗠𝗮𝘆 𝘆𝗼𝘂 𝗴𝗲𝘁 𝘀𝘂𝗲𝗱 𝗳𝗼𝗿 𝗰𝗼𝗽𝘆𝗿𝗶𝗴𝗵𝘁 𝗶𝗻𝗳𝗿𝗶𝗻𝗴𝗲𝗺𝗲𝗻𝘁 𝘂𝗻𝘁𝗶𝗹 𝘆𝗼𝘂'𝗿𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗹𝘆 𝗯𝗿𝗼𝗸𝗲, 𝗮𝗹𝗹 𝘆𝗼𝘂𝗿 𝗮𝗰𝗰𝗼𝘂𝗻𝘁𝘀 𝗴𝗲𝘁 𝘀𝗵𝗮𝗱𝗼𝘄𝗯𝗮𝗻𝗻𝗲𝗱 𝗮𝗻𝗱 𝘀𝘂𝘀𝗽𝗲𝗻𝗱𝗲𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗿𝗲𝘀𝘁 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗹𝗶𝗳𝗲." LINGLING APAC FACE OF CK #CalvinKleinSS27xLINGLING #LinglingkwongxCalvinklein #CalvinKleinSS27 #NYFW #CalvinKlein #LinglingKwong

Mnz 'ภีรชน์

33,515 görüntüleme • 5 gün önce

‘𝗧𝗲𝗹𝗹 𝗠𝗿 𝗧𝗿𝘂𝗺𝗽 𝘄𝗲 𝗮𝗿𝗲 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗵𝗶𝘀 𝗯𝗼𝗺𝗯𝘀’𝘵𝘩𝘦 𝘱𝘦𝘰𝘱𝘭𝘦 𝘰𝘧 𝘐𝘳𝘢𝘯 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘣𝘦 𝘧𝘳𝘦𝘦! “𝗧𝗵𝗶𝘀 𝗴𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝘄𝗶𝗹𝗹 𝘀𝗵𝗮𝗸𝗲 𝘆𝗼𝘂𝗿 𝗵𝗮𝗻𝗱 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗵𝗮𝗻𝗱 𝗮𝗻𝗱 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗲𝗻𝗿𝗶𝗰𝗵𝗶𝗻𝗴 𝘂𝗿𝗮𝗻𝗶𝘂𝗺 𝗶𝗻 𝘀𝗲𝗰𝗿𝗲𝘁 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗹𝗲𝗳𝘁 𝗵𝗮𝗻𝗱. 𝗗𝗲𝗺𝗼𝗰𝗿𝗮𝘁𝘀 𝗮𝗿𝗲 𝗻𝗮𝗶𝘃𝗲 𝗮𝗻𝗱 𝗻𝗮𝗿𝗰𝗶𝘀𝘀𝗶𝘀𝘁𝗶𝗰 ! 𝗧𝗵𝗲 𝗼𝗻𝗹𝘆 𝗹𝗮𝗻𝗴𝘂𝗮𝗴𝗲 𝘁𝗵𝗶𝘀 𝗿𝗲𝗴𝗶𝗺𝗲 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝘀 𝗶𝘀 𝗳𝗼𝗿𝗰𝗲!”

‘𝗧𝗲𝗹𝗹 𝗠𝗿 𝗧𝗿𝘂𝗺𝗽 𝘄𝗲 𝗮𝗿𝗲 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗵𝗶𝘀 𝗯𝗼𝗺𝗯𝘀’𝘵𝘩𝘦 𝘱𝘦𝘰𝘱𝘭𝘦 𝘰𝘧 𝘐𝘳𝘢𝘯 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘣𝘦 𝘧𝘳𝘦𝘦! “𝗧𝗵𝗶𝘀 𝗴𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝘄𝗶𝗹𝗹 𝘀𝗵𝗮𝗸𝗲 𝘆𝗼𝘂𝗿 𝗵𝗮𝗻𝗱 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗵𝗮𝗻𝗱 𝗮𝗻𝗱 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗲𝗻𝗿𝗶𝗰𝗵𝗶𝗻𝗴 𝘂𝗿𝗮𝗻𝗶𝘂𝗺 𝗶𝗻 𝘀𝗲𝗰𝗿𝗲𝘁 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗹𝗲𝗳𝘁 𝗵𝗮𝗻𝗱. 𝗗𝗲𝗺𝗼𝗰𝗿𝗮𝘁𝘀 𝗮𝗿𝗲 𝗻𝗮𝗶𝘃𝗲 𝗮𝗻𝗱 𝗻𝗮𝗿𝗰𝗶𝘀𝘀𝗶𝘀𝘁𝗶𝗰 ! 𝗧𝗵𝗲 𝗼𝗻𝗹𝘆 𝗹𝗮𝗻𝗴𝘂𝗮𝗴𝗲 𝘁𝗵𝗶𝘀 𝗿𝗲𝗴𝗶𝗺𝗲 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝘀 𝗶𝘀 𝗳𝗼𝗿𝗰𝗲!”

AMERICANVibes

57,333 görüntüleme • 1 yıl önce

🚨 𝗜𝗻 𝘁𝗵𝗲 𝗵𝗲𝗮𝗿𝘁 𝗼𝗳 𝗪𝗮𝘀𝗵𝗶𝗻𝗴𝘁𝗼𝗻: 𝗧𝗿𝘂𝗺𝗽 𝗮𝗻𝗱 𝗵𝗶𝘀 𝗩𝗣 𝘄𝗲𝗿𝗲 𝘁𝗵𝗿𝗼𝘄𝗻 𝗼𝘂𝘁 𝗼𝗳 𝗮 𝗿𝗲𝘀𝘁𝗮𝘂𝗿𝗮𝗻𝘁 over their 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗳𝗼𝗿 𝗜𝘀𝗿𝗮𝗲𝗹. Not a protest in 𝗟𝗼𝗻𝗱𝗼𝗻. Not a chant in 𝗣𝗮𝗿𝗶𝘀. 𝗧𝗵𝗶𝘀 𝗶𝘀 𝗶𝗻𝘀𝗶𝗱𝗲 𝘁𝗵𝗲 𝗲𝗺𝗽𝗶𝗿𝗲'𝘀 𝗼𝘄𝗻 𝗰𝗮𝗽𝗶𝘁𝗮𝗹. 𝗪𝗵𝗲𝗻 𝘆𝗼𝘂𝗿 𝗼𝘄𝗻 𝗽𝗲𝗼𝗽𝗹𝗲 𝘁𝗵𝗿𝗼𝘄 𝘆𝗼𝘂 𝗼𝘂𝘁 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗱𝗶𝗻𝗻𝗲𝗿… you're no longer a president. 𝗬𝗼𝘂'𝗿𝗲 𝗮 𝗯𝘂𝗿𝗻𝘁 𝗰𝗮𝗿𝗱. The American wave against Israel no longer comes from universities. It's coming from 𝗿𝗲𝘀𝘁𝗮𝘂𝗿𝗮𝗻𝘁𝘀, 𝘀𝘁𝗿𝗲𝗲𝘁𝘀, 𝗮𝗻𝗱 𝗰𝗮𝗳é𝘀. 𝗧𝗵𝗶𝘀 𝗶𝘀 𝗮 𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗽𝗼𝗶𝗻𝘁 — one no poll can measure.

🚨 𝗜𝗻 𝘁𝗵𝗲 𝗵𝗲𝗮𝗿𝘁 𝗼𝗳 𝗪𝗮𝘀𝗵𝗶𝗻𝗴𝘁𝗼𝗻: 𝗧𝗿𝘂𝗺𝗽 𝗮𝗻𝗱 𝗵𝗶𝘀 𝗩𝗣 𝘄𝗲𝗿𝗲 𝘁𝗵𝗿𝗼𝘄𝗻 𝗼𝘂𝘁 𝗼𝗳 𝗮 𝗿𝗲𝘀𝘁𝗮𝘂𝗿𝗮𝗻𝘁 over their 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗳𝗼𝗿 𝗜𝘀𝗿𝗮𝗲𝗹. Not a protest in 𝗟𝗼𝗻𝗱𝗼𝗻. Not a chant in 𝗣𝗮𝗿𝗶𝘀. 𝗧𝗵𝗶𝘀 𝗶𝘀 𝗶𝗻𝘀𝗶𝗱𝗲 𝘁𝗵𝗲 𝗲𝗺𝗽𝗶𝗿𝗲'𝘀 𝗼𝘄𝗻 𝗰𝗮𝗽𝗶𝘁𝗮𝗹. 𝗪𝗵𝗲𝗻 𝘆𝗼𝘂𝗿 𝗼𝘄𝗻 𝗽𝗲𝗼𝗽𝗹𝗲 𝘁𝗵𝗿𝗼𝘄 𝘆𝗼𝘂 𝗼𝘂𝘁 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗱𝗶𝗻𝗻𝗲𝗿… you're no longer a president. 𝗬𝗼𝘂'𝗿𝗲 𝗮 𝗯𝘂𝗿𝗻𝘁 𝗰𝗮𝗿𝗱. The American wave against Israel no longer comes from universities. It's coming from 𝗿𝗲𝘀𝘁𝗮𝘂𝗿𝗮𝗻𝘁𝘀, 𝘀𝘁𝗿𝗲𝗲𝘁𝘀, 𝗮𝗻𝗱 𝗰𝗮𝗳é𝘀. 𝗧𝗵𝗶𝘀 𝗶𝘀 𝗮 𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗽𝗼𝗶𝗻𝘁 — one no poll can measure.

SilencedSirs◼️

97,698 görüntüleme • 5 ay önce

I spent 14 grueling months trying to monetize on X. I burnt out & wanted to quit. Until I made it happen & put the process into a notion document. 𝗜𝘁'𝘀 𝗳𝗿𝗲𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝟮𝟰 𝗵𝗼𝘂𝗿𝘀. Like & comment "$" & I'll send it your way. (Follow so I can DM)

I spent 14 grueling months trying to monetize on X. I burnt out & wanted to quit. Until I made it happen & put the process into a notion document. 𝗜𝘁'𝘀 𝗳𝗿𝗲𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝟮𝟰 𝗵𝗼𝘂𝗿𝘀. Like & comment "$" & I'll send it your way. (Follow so I can DM)

George Hernandez

18,910 görüntüleme • 2 yıl önce

𝗧𝘂𝗿𝗻 𝘆𝗼𝘂𝗿 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀 𝘂𝗽. 🔥🔥🔥 𝗧𝗵𝗶𝘀 𝘀𝗼𝗻𝗴 𝗶𝘀 𝗮 𝘃𝗶𝗰𝘁𝗼𝗿𝘆 𝗹𝗮𝗽 𝗳𝗼𝗿 𝗖𝗮𝘁𝗵𝗼𝗹𝗶𝗰𝘀 𝗲𝘃𝗲𝗿𝘆𝘄𝗵𝗲𝗿𝗲. Peter’s Barque just dropped “Hasn’t Changed A Thing”, and it is a 𝘧𝘪𝘴𝘵 𝘱𝘶𝘮𝘱 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘊𝘢𝘵𝘩𝘰𝘭𝘪𝘤 𝘴𝘰𝘶𝘭. Every century begged the Church to update with the culture. Every denomination bent. 𝗕𝘂𝘁 𝘁𝗵𝗲 𝗖𝗮𝘁𝗵𝗼𝗹𝗶𝗰 𝗖𝗵𝘂𝗿𝗰𝗵 𝘀𝘁𝗼𝗼𝗱 𝗳𝗶𝗿𝗺, preaching the same Gospel she received once for all. Protestantism keeps reinventing itself. 𝐑𝐨𝐦𝐞 𝐧𝐞𝐯𝐞𝐫 𝐡𝐚𝐝 𝐭𝐨. ✌️

𝗧𝘂𝗿𝗻 𝘆𝗼𝘂𝗿 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀 𝘂𝗽. 🔥🔥🔥 𝗧𝗵𝗶𝘀 𝘀𝗼𝗻𝗴 𝗶𝘀 𝗮 𝘃𝗶𝗰𝘁𝗼𝗿𝘆 𝗹𝗮𝗽 𝗳𝗼𝗿 𝗖𝗮𝘁𝗵𝗼𝗹𝗶𝗰𝘀 𝗲𝘃𝗲𝗿𝘆𝘄𝗵𝗲𝗿𝗲. Peter’s Barque just dropped “Hasn’t Changed A Thing”, and it is a 𝘧𝘪𝘴𝘵 𝘱𝘶𝘮𝘱 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘊𝘢𝘵𝘩𝘰𝘭𝘪𝘤 𝘴𝘰𝘶𝘭. Every century begged the Church to update with the culture. Every denomination bent. 𝗕𝘂𝘁 𝘁𝗵𝗲 𝗖𝗮𝘁𝗵𝗼𝗹𝗶𝗰 𝗖𝗵𝘂𝗿𝗰𝗵 𝘀𝘁𝗼𝗼𝗱 𝗳𝗶𝗿𝗺, preaching the same Gospel she received once for all. Protestantism keeps reinventing itself. 𝐑𝐨𝐦𝐞 𝐧𝐞𝐯𝐞𝐫 𝐡𝐚𝐝 𝐭𝐨. ✌️

𝚕𝚒𝚝𝚝𝚕𝚎 𝚘𝚗𝚎 ♱🇻🇦

50,027 görüntüleme • 9 ay önce

𝗖𝗵𝗶𝗻𝗮 𝗷𝘂𝘀𝘁 𝗿𝗲𝗹𝗲𝗮𝘀𝗲𝗱 𝘁𝗵𝗲 #𝟭 𝗼𝗽𝗲𝗻-𝘀𝗼𝘂𝗿𝗰𝗲 𝗶𝗺𝗮𝗴𝗲 𝗺𝗼𝗱𝗲𝗹. 𝗬𝗼𝘂'𝗿𝗲 𝘀𝘁𝗶𝗹𝗹 𝗽𝗮𝘆𝗶𝗻𝗴 𝗳𝗼𝗿 𝗠𝗶𝗱𝗷𝗼𝘂𝗿𝗻𝗲𝘆. 𝗤𝘄𝗲𝗻 𝗜𝗺𝗮𝗴𝗲 𝟮.𝟱 𝗶𝘀 𝗳𝗿𝗲𝗲. 𝗔𝗻𝗱 𝗶𝘁 𝗿𝘂𝗻𝘀 𝗼𝗻 𝘆𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝘂𝘁𝗲𝗿. I tested it against ChatGPT and Gemini. Here's what happened: 1: Qwen generated images 3x faster 2: Zero limits on what you create 3: No cloud required 4: Beat paid models on editing tests 5: Runs locally with no monthly fees Open source means no restrictions. Less than 1% of creators know this exists. Save this video, you'll cancel your subscriptions. Want the SOP? DM me. 💬

𝗖𝗵𝗶𝗻𝗮 𝗷𝘂𝘀𝘁 𝗿𝗲𝗹𝗲𝗮𝘀𝗲𝗱 𝘁𝗵𝗲 #𝟭 𝗼𝗽𝗲𝗻-𝘀𝗼𝘂𝗿𝗰𝗲 𝗶𝗺𝗮𝗴𝗲 𝗺𝗼𝗱𝗲𝗹. 𝗬𝗼𝘂'𝗿𝗲 𝘀𝘁𝗶𝗹𝗹 𝗽𝗮𝘆𝗶𝗻𝗴 𝗳𝗼𝗿 𝗠𝗶𝗱𝗷𝗼𝘂𝗿𝗻𝗲𝘆. 𝗤𝘄𝗲𝗻 𝗜𝗺𝗮𝗴𝗲 𝟮.𝟱 𝗶𝘀 𝗳𝗿𝗲𝗲. 𝗔𝗻𝗱 𝗶𝘁 𝗿𝘂𝗻𝘀 𝗼𝗻 𝘆𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝘂𝘁𝗲𝗿. I tested it against ChatGPT and Gemini. Here's what happened: 1: Qwen generated images 3x faster 2: Zero limits on what you create 3: No cloud required 4: Beat paid models on editing tests 5: Runs locally with no monthly fees Open source means no restrictions. Less than 1% of creators know this exists. Save this video, you'll cancel your subscriptions. Want the SOP? DM me. 💬

Julian Goldie SEO

53,028 görüntüleme • 8 ay önce

𝗘𝗶𝗴𝗵𝘁𝗲𝗲𝗻 𝘆𝗲𝗮𝗿𝘀 𝗮𝗴𝗼, a little girl began writing a story she never knew would touch so many lives. Today, 𝘄𝗲 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲 𝗲𝘃𝗲𝗿𝘆 𝗽𝗮𝗴𝗲 𝗼𝗳 𝘁𝗵𝗮𝘁 𝘀𝘁𝗼𝗿𝘆. From the little girl whose smile could brighten any room, to the young woman who continues to inspire through her 𝘁𝗮𝗹𝗲𝗻𝘁, 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗴𝗲𝗻𝘂𝗶𝗻𝗲 𝗵𝗲𝗮𝗿𝘁—you have grown into someone 𝘄𝗲 𝗮𝗿𝗲 𝗲𝗻𝗱𝗹𝗲𝘀𝘀𝗹𝘆 𝗽𝗿𝗼𝘂𝗱 𝗼𝗳. This video is more than a collection of clips. 𝗜𝘁 𝗶𝘀 𝗮 𝗷𝗼𝘂𝗿𝗻𝗲𝘆 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗲𝘃𝗲𝗿𝘆 𝗰𝗵𝗮𝗽𝘁𝗲𝗿 𝘁𝗵𝗮𝘁 𝘀𝗵𝗮𝗽𝗲𝗱 𝘆𝗼𝘂. The childhood memories, the first steps toward your dreams, the projects that introduced you to the world, the milestones you worked so hard to achieve, the victories worth celebrating, and the countless moments that revealed 𝘁𝗵𝗲 𝗸𝗶𝗻𝗱 𝗼𝗳 𝗽𝗲𝗿𝘀𝗼𝗻 𝘆𝗼𝘂 𝘁𝗿𝘂𝗹𝘆 𝗮𝗿𝗲. Behind every achievement is 𝘆𝗼𝘂𝗿 𝗽𝗲𝗿𝘀𝗲𝘃𝗲𝗿𝗮𝗻𝗰𝗲. Behind every role is 𝘆𝗼𝘂𝗿 𝗽𝗮𝘀𝘀𝗶𝗼𝗻. And behind every success is 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝗵𝘂𝗺𝗯𝗹𝗲, 𝗸𝗶𝗻𝗱-𝗵𝗲𝗮𝗿𝘁𝗲𝗱 𝗞𝗿𝘆𝘀𝘁𝗮𝗹 who has never forgotten to make people feel seen and loved. 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗮𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝘂𝘀 𝘁𝗼 𝘄𝗶𝘁𝗻𝗲𝘀𝘀 𝘆𝗼𝘂𝗿 𝗴𝗿𝗼𝘄𝘁𝗵—not only as an artist, but as a person. Watching you chase your dreams has inspired us to believe in our own, and watching you remain genuine through it all has made us 𝗮𝗱𝗺𝗶𝗿𝗲 𝘆𝗼𝘂 𝗲𝘃𝗲𝗻 𝗺𝗼𝗿𝗲. As you turn eighteen, we hope you continue to embrace 𝗲𝘃𝗲𝗿𝘆 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆, 𝗲𝘃𝗲𝗿𝘆 𝗹𝗲𝘀𝘀𝗼𝗻, 𝗮𝗻𝗱 𝗲𝘃𝗲𝗿𝘆 𝗱𝗿𝗲𝗮𝗺 waiting to be fulfilled. May this new chapter be filled with 𝗲𝘃𝗲𝗻 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗮𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀, 𝘂𝗻𝗳𝗼𝗿𝗴𝗲𝘁𝘁𝗮𝗯𝗹𝗲 𝗺𝗲𝗺𝗼𝗿𝗶𝗲𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗵𝗮𝗽𝗽𝗶𝗻𝗲𝘀𝘀 𝘆𝗼𝘂 𝗱𝗲𝘀𝗲𝗿𝘃𝗲. 𝗧𝗵𝗲 𝗹𝗶𝘁𝘁𝗹𝗲 𝗴𝗶𝗿𝗹 𝘄𝗵𝗼 𝗼𝗻𝗰𝗲 𝗱𝗿𝗲𝗮𝗺𝗲𝗱 𝗵𝗮𝘀 𝗯𝗲𝗰𝗼𝗺𝗲 𝗮 𝘆𝗼𝘂𝗻𝗴 𝘄𝗼𝗺𝗮𝗻 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝗶𝗻𝘀𝗽𝗶𝗿𝗲 𝘁𝗵𝗼𝘂𝘀𝗮𝗻𝗱𝘀—and 𝘁𝗵𝗶𝘀 𝗶𝘀 𝗼𝗻𝗹𝘆 𝘁𝗵𝗲 𝗯𝗲𝗴𝗶𝗻𝗻𝗶𝗻𝗴 𝗼𝗳 𝗮𝗻 𝗲𝘃𝗲𝗻 𝗺𝗼𝗿𝗲 𝗯𝗲𝗮𝘂𝘁𝗶𝗳𝘂𝗹 𝗷𝗼𝘂𝗿𝗻𝗲𝘆. 𝗛𝗮𝗽𝗽𝘆 𝟭𝟴𝘁𝗵 𝗕𝗶𝗿𝘁𝗵𝗱𝗮𝘆, 𝗞𝗿𝘆𝘀𝘁𝗮𝗹. 🤍 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗲𝘃𝗲𝗿𝘆 𝗺𝗲𝗺𝗼𝗿𝘆 𝘆𝗼𝘂'𝘃𝗲 𝗴𝗶𝘃𝗲𝗻 𝘂𝘀. Here's to celebrating 𝗮𝗹𝗹 𝘁𝗵𝗮𝘁 𝘆𝗼𝘂'𝘃𝗲 𝗮𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗲𝗱, and to 𝗲𝘃𝗲𝗿𝘆 𝗶𝗻𝗰𝗿𝗲𝗱𝗶𝗯𝗹𝗲 𝗰𝗵𝗮𝗽𝘁𝗲𝗿 𝘁𝗵𝗮𝘁 𝗶𝘀 𝘀𝘁𝗶𝗹𝗹 𝘄𝗮𝗶𝘁𝗶𝗻𝗴 𝘁𝗼 𝗯𝗲 𝘄𝗿𝗶𝘁𝘁𝗲𝗻. 𝗪𝗶𝘁𝗵 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗹𝗼𝘃𝗲, 𝗬𝗼𝘂𝗿 𝗧𝗮𝗹𝗶𝗮𝗻𝘀. 🤍 KRYSTAL MEJES TURNS EIGHTEEN #TALA18DDAY

𝗘𝗶𝗴𝗵𝘁𝗲𝗲𝗻 𝘆𝗲𝗮𝗿𝘀 𝗮𝗴𝗼, a little girl began writing a story she never knew would touch so many lives. Today, 𝘄𝗲 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲 𝗲𝘃𝗲𝗿𝘆 𝗽𝗮𝗴𝗲 𝗼𝗳 𝘁𝗵𝗮𝘁 𝘀𝘁𝗼𝗿𝘆. From the little girl whose smile could brighten any room, to the young woman who continues to inspire through her 𝘁𝗮𝗹𝗲𝗻𝘁, 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗴𝗲𝗻𝘂𝗶𝗻𝗲 𝗵𝗲𝗮𝗿𝘁—you have grown into someone 𝘄𝗲 𝗮𝗿𝗲 𝗲𝗻𝗱𝗹𝗲𝘀𝘀𝗹𝘆 𝗽𝗿𝗼𝘂𝗱 𝗼𝗳. This video is more than a collection of clips. 𝗜𝘁 𝗶𝘀 𝗮 𝗷𝗼𝘂𝗿𝗻𝗲𝘆 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗲𝘃𝗲𝗿𝘆 𝗰𝗵𝗮𝗽𝘁𝗲𝗿 𝘁𝗵𝗮𝘁 𝘀𝗵𝗮𝗽𝗲𝗱 𝘆𝗼𝘂. The childhood memories, the first steps toward your dreams, the projects that introduced you to the world, the milestones you worked so hard to achieve, the victories worth celebrating, and the countless moments that revealed 𝘁𝗵𝗲 𝗸𝗶𝗻𝗱 𝗼𝗳 𝗽𝗲𝗿𝘀𝗼𝗻 𝘆𝗼𝘂 𝘁𝗿𝘂𝗹𝘆 𝗮𝗿𝗲. Behind every achievement is 𝘆𝗼𝘂𝗿 𝗽𝗲𝗿𝘀𝗲𝘃𝗲𝗿𝗮𝗻𝗰𝗲. Behind every role is 𝘆𝗼𝘂𝗿 𝗽𝗮𝘀𝘀𝗶𝗼𝗻. And behind every success is 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝗵𝘂𝗺𝗯𝗹𝗲, 𝗸𝗶𝗻𝗱-𝗵𝗲𝗮𝗿𝘁𝗲𝗱 𝗞𝗿𝘆𝘀𝘁𝗮𝗹 who has never forgotten to make people feel seen and loved. 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗮𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝘂𝘀 𝘁𝗼 𝘄𝗶𝘁𝗻𝗲𝘀𝘀 𝘆𝗼𝘂𝗿 𝗴𝗿𝗼𝘄𝘁𝗵—not only as an artist, but as a person. Watching you chase your dreams has inspired us to believe in our own, and watching you remain genuine through it all has made us 𝗮𝗱𝗺𝗶𝗿𝗲 𝘆𝗼𝘂 𝗲𝘃𝗲𝗻 𝗺𝗼𝗿𝗲. As you turn eighteen, we hope you continue to embrace 𝗲𝘃𝗲𝗿𝘆 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆, 𝗲𝘃𝗲𝗿𝘆 𝗹𝗲𝘀𝘀𝗼𝗻, 𝗮𝗻𝗱 𝗲𝘃𝗲𝗿𝘆 𝗱𝗿𝗲𝗮𝗺 waiting to be fulfilled. May this new chapter be filled with 𝗲𝘃𝗲𝗻 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗮𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀, 𝘂𝗻𝗳𝗼𝗿𝗴𝗲𝘁𝘁𝗮𝗯𝗹𝗲 𝗺𝗲𝗺𝗼𝗿𝗶𝗲𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗵𝗮𝗽𝗽𝗶𝗻𝗲𝘀𝘀 𝘆𝗼𝘂 𝗱𝗲𝘀𝗲𝗿𝘃𝗲. 𝗧𝗵𝗲 𝗹𝗶𝘁𝘁𝗹𝗲 𝗴𝗶𝗿𝗹 𝘄𝗵𝗼 𝗼𝗻𝗰𝗲 𝗱𝗿𝗲𝗮𝗺𝗲𝗱 𝗵𝗮𝘀 𝗯𝗲𝗰𝗼𝗺𝗲 𝗮 𝘆𝗼𝘂𝗻𝗴 𝘄𝗼𝗺𝗮𝗻 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝗶𝗻𝘀𝗽𝗶𝗿𝗲 𝘁𝗵𝗼𝘂𝘀𝗮𝗻𝗱𝘀—and 𝘁𝗵𝗶𝘀 𝗶𝘀 𝗼𝗻𝗹𝘆 𝘁𝗵𝗲 𝗯𝗲𝗴𝗶𝗻𝗻𝗶𝗻𝗴 𝗼𝗳 𝗮𝗻 𝗲𝘃𝗲𝗻 𝗺𝗼𝗿𝗲 𝗯𝗲𝗮𝘂𝘁𝗶𝗳𝘂𝗹 𝗷𝗼𝘂𝗿𝗻𝗲𝘆. 𝗛𝗮𝗽𝗽𝘆 𝟭𝟴𝘁𝗵 𝗕𝗶𝗿𝘁𝗵𝗱𝗮𝘆, 𝗞𝗿𝘆𝘀𝘁𝗮𝗹. 🤍 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗲𝘃𝗲𝗿𝘆 𝗺𝗲𝗺𝗼𝗿𝘆 𝘆𝗼𝘂'𝘃𝗲 𝗴𝗶𝘃𝗲𝗻 𝘂𝘀. Here's to celebrating 𝗮𝗹𝗹 𝘁𝗵𝗮𝘁 𝘆𝗼𝘂'𝘃𝗲 𝗮𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗲𝗱, and to 𝗲𝘃𝗲𝗿𝘆 𝗶𝗻𝗰𝗿𝗲𝗱𝗶𝗯𝗹𝗲 𝗰𝗵𝗮𝗽𝘁𝗲𝗿 𝘁𝗵𝗮𝘁 𝗶𝘀 𝘀𝘁𝗶𝗹𝗹 𝘄𝗮𝗶𝘁𝗶𝗻𝗴 𝘁𝗼 𝗯𝗲 𝘄𝗿𝗶𝘁𝘁𝗲𝗻. 𝗪𝗶𝘁𝗵 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗹𝗼𝘃𝗲, 𝗬𝗼𝘂𝗿 𝗧𝗮𝗹𝗶𝗮𝗻𝘀. 🤍 KRYSTAL MEJES TURNS EIGHTEEN #TALA18DDAY

TEAM KRYSTAL OFFICIAL

46,643 görüntüleme • 2 ay önce

𝗧𝗵𝗲 𝗗𝗮𝘆 𝗼𝗳 𝗟𝗶𝗻𝗴𝗹𝗶𝗻𝗴 𝗜𝘀 𝗛𝗲𝗿𝗲 𝗕𝗶𝗿𝘁𝗵𝗱𝗮𝘆 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗣𝗮𝗿𝘁 𝗜𝗩 – 𝗕𝗹𝗼𝗼𝗺𝗶𝗻𝗴 𝗔𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗕𝗶𝗴 𝗦𝗰𝗿𝗲𝗲𝗻, 𝗟𝗶𝗴𝗵𝘁𝗶𝗻𝗴 𝗨𝗽 𝘁𝗵𝗲 𝗖𝗶𝘁𝘆 𝗳𝗼𝗿 𝗟𝗶𝗻𝗴𝗹𝗶𝗻𝗴’𝘀 𝗗𝗮𝘆 💙 วันสำคัญของ “พี่หลิงหลิง” ปีนี้ รอยยิ้ม ความน่ารัก และเสน่ห์ของพี่หลิงกำลังจะถูกส่งขึ้นไปเปล่งประกายอยู่บนจอใหญ่ใจกลางเมือง ✨ จากความรักเล็ก ๆ ของพวกเรา สู่จอแลนด์มาร์กกลางเมืองที่อบอวลไปด้วยความภูมิใจ เพื่อร่วมกันบันทึกภาพแห่งการเติบโตและช่วงเวลาที่สวยงามของ “พี่หลิง” 🤍 “𝗕𝗹𝗼𝗼𝗶𝗺𝗴” คือคำที่พวกเราใช้แทนทุกความทรงจำ และการเติบโตของพี่หลิงผ่านภาพ แสง และ สี ✨ 𝗜𝗻𝘀𝗽𝗶𝗿𝗲𝗱 𝗯𝘆 “𝗕𝗹𝗼𝗼𝗺𝗶𝗻𝗴” - การเบ่งบานและการเปล่งประกายอย่างสวยงาม “𝗜𝗺𝗮𝗴𝗲” - ภาพความทรงจำที่พวกเราอยากบันทึกไว้ตลอดไป 💙 ให้ทุกภาพที่ปรากฏขึ้นบนหน้าจอ ทุกแสงที่ถูกส่งออกไปเป็นเหมือนตัวแทนของความรัก ความภูมิใจ และการเดินทางของพี่หลิงที่ค่อย ๆ เติบโตขึ้นจนเปล่งประกายอยู่ท่ามกลางเมืองใหญ่ในวันนี้ 🌸 พวกเราอยากให้ “พี่หลิง” ได้รับความรักที่ถูกรายล้อมไปด้วยรอยยิ้ม และความอบอุ่น รวมถึงการได้ถูกค้นพบจากผู้คนอีกมากมาย เหมือนกับที่พวกเรารัก และภูมิใจในตัวพี่หลิงมาโดยตลอด 🥹💫 📍𝗟𝗢𝗖𝗔𝗧𝗜𝗢𝗡 - 𝗣𝗮𝗿𝗰 𝗣𝗮𝗿𝗮𝗴𝗼𝗻 - 𝗜𝗻𝘁𝗲𝗿𝗰𝗵𝗮𝗻𝗴𝗲 𝟮𝟭 (สี่แยกอโศก) 🗓 𝗗𝗔𝗧𝗘 : 𝟵–𝟭𝟭 𝗠𝗔𝗬 𝟮𝟬𝟮𝟲 🕕 𝗦𝗖𝗥𝗘𝗘𝗡 𝗧𝗜𝗠𝗘 : 𝟬𝟲:𝟬𝟬–𝟮𝟰:𝟬𝟬 (𝟭𝟴 𝗛𝗢𝗨𝗥𝗦/𝗗𝗔𝗬) 🎬 𝗦𝗣𝗢𝗧 𝗟𝗘𝗡𝗚𝗧𝗛 : 𝟯𝟬 𝗦𝗘𝗖𝗢𝗡𝗗𝗦/𝗦𝗣𝗢𝗧 🔁 𝗟𝗢𝗢𝗣 𝗗𝗨𝗥𝗔𝗧𝗜𝗢𝗡 : 𝟮 𝗠𝗜𝗡𝗨𝗧𝗘𝗦/𝗟𝗢𝗢𝗣 ☝🏼 𝗡𝗨𝗠𝗕𝗘𝗥 𝗢𝗙 𝗦𝗣𝗢𝗧𝗦 : 𝟰 𝗦𝗣𝗢𝗧𝗦/𝗟𝗢𝗢𝗣𝗣𝗔𝗥𝗖 หวังว่าโปรเจกต์นี้จะกลายเป็นอีกหนึ่งความทรงจำดี ๆ ของทุกคนนะคะ แล้วไปเก็บ โมเมนต์สวย ๆ ของพี่หลิงด้วยกันค่ะ อย่าลืมเอามาอวดกันด้วยน๊าาาาคะ 🫶🏻 #linglingkwong #หลิงหลิงคอง #linglingkwong_official #AngelGolden

𝗧𝗵𝗲 𝗗𝗮𝘆 𝗼𝗳 𝗟𝗶𝗻𝗴𝗹𝗶𝗻𝗴 𝗜𝘀 𝗛𝗲𝗿𝗲 𝗕𝗶𝗿𝘁𝗵𝗱𝗮𝘆 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗣𝗮𝗿𝘁 𝗜𝗩 – 𝗕𝗹𝗼𝗼𝗺𝗶𝗻𝗴 𝗔𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗕𝗶𝗴 𝗦𝗰𝗿𝗲𝗲𝗻, 𝗟𝗶𝗴𝗵𝘁𝗶𝗻𝗴 𝗨𝗽 𝘁𝗵𝗲 𝗖𝗶𝘁𝘆 𝗳𝗼𝗿 𝗟𝗶𝗻𝗴𝗹𝗶𝗻𝗴’𝘀 𝗗𝗮𝘆 💙 วันสำคัญของ “พี่หลิงหลิง” ปีนี้ รอยยิ้ม ความน่ารัก และเสน่ห์ของพี่หลิงกำลังจะถูกส่งขึ้นไปเปล่งประกายอยู่บนจอใหญ่ใจกลางเมือง ✨ จากความรักเล็ก ๆ ของพวกเรา สู่จอแลนด์มาร์กกลางเมืองที่อบอวลไปด้วยความภูมิใจ เพื่อร่วมกันบันทึกภาพแห่งการเติบโตและช่วงเวลาที่สวยงามของ “พี่หลิง” 🤍 “𝗕𝗹𝗼𝗼𝗶𝗺𝗴” คือคำที่พวกเราใช้แทนทุกความทรงจำ และการเติบโตของพี่หลิงผ่านภาพ แสง และ สี ✨ 𝗜𝗻𝘀𝗽𝗶𝗿𝗲𝗱 𝗯𝘆 “𝗕𝗹𝗼𝗼𝗺𝗶𝗻𝗴” - การเบ่งบานและการเปล่งประกายอย่างสวยงาม “𝗜𝗺𝗮𝗴𝗲” - ภาพความทรงจำที่พวกเราอยากบันทึกไว้ตลอดไป 💙 ให้ทุกภาพที่ปรากฏขึ้นบนหน้าจอ ทุกแสงที่ถูกส่งออกไปเป็นเหมือนตัวแทนของความรัก ความภูมิใจ และการเดินทางของพี่หลิงที่ค่อย ๆ เติบโตขึ้นจนเปล่งประกายอยู่ท่ามกลางเมืองใหญ่ในวันนี้ 🌸 พวกเราอยากให้ “พี่หลิง” ได้รับความรักที่ถูกรายล้อมไปด้วยรอยยิ้ม และความอบอุ่น รวมถึงการได้ถูกค้นพบจากผู้คนอีกมากมาย เหมือนกับที่พวกเรารัก และภูมิใจในตัวพี่หลิงมาโดยตลอด 🥹💫 📍𝗟𝗢𝗖𝗔𝗧𝗜𝗢𝗡 - 𝗣𝗮𝗿𝗰 𝗣𝗮𝗿𝗮𝗴𝗼𝗻 - 𝗜𝗻𝘁𝗲𝗿𝗰𝗵𝗮𝗻𝗴𝗲 𝟮𝟭 (สี่แยกอโศก) 🗓 𝗗𝗔𝗧𝗘 : 𝟵–𝟭𝟭 𝗠𝗔𝗬 𝟮𝟬𝟮𝟲 🕕 𝗦𝗖𝗥𝗘𝗘𝗡 𝗧𝗜𝗠𝗘 : 𝟬𝟲:𝟬𝟬–𝟮𝟰:𝟬𝟬 (𝟭𝟴 𝗛𝗢𝗨𝗥𝗦/𝗗𝗔𝗬) 🎬 𝗦𝗣𝗢𝗧 𝗟𝗘𝗡𝗚𝗧𝗛 : 𝟯𝟬 𝗦𝗘𝗖𝗢𝗡𝗗𝗦/𝗦𝗣𝗢𝗧 🔁 𝗟𝗢𝗢𝗣 𝗗𝗨𝗥𝗔𝗧𝗜𝗢𝗡 : 𝟮 𝗠𝗜𝗡𝗨𝗧𝗘𝗦/𝗟𝗢𝗢𝗣 ☝🏼 𝗡𝗨𝗠𝗕𝗘𝗥 𝗢𝗙 𝗦𝗣𝗢𝗧𝗦 : 𝟰 𝗦𝗣𝗢𝗧𝗦/𝗟𝗢𝗢𝗣𝗣𝗔𝗥𝗖 หวังว่าโปรเจกต์นี้จะกลายเป็นอีกหนึ่งความทรงจำดี ๆ ของทุกคนนะคะ แล้วไปเก็บ โมเมนต์สวย ๆ ของพี่หลิงด้วยกันค่ะ อย่าลืมเอามาอวดกันด้วยน๊าาาาคะ 🫶🏻 #linglingkwong #หลิงหลิงคอง #linglingkwong_official #AngelGolden

Linglingkwong_Official

16,552 görüntüleme • 4 ay önce

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗛𝘂𝗺𝗮𝗻𝘀™️ — trainable AI beings that transform the ways teams can research and innovate.⁠ ⁠ Each Synthetic Human is trained on real, human data to have a complex personality, modeled on over 100 attributes of the human psyche. Each human has long-term memory and the ability to see.⁠ ⁠ What can you do with them?⁠ ⁠ 𝗨𝘀𝗲 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗛𝘂𝗺𝗮𝗻𝘀 𝗳𝗼𝗿 𝗨𝘀𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵:⁠ ▪️ Securely mirror your existing and desired customers at global scale.⁠ ▪️ Then run both qualitative and quantitative research studies with high degrees of accuracy.⁠ ▪️ Build empathy directly with individuals.⁠ ▪️ Create research communities that remember and evolve.⁠ ▪️ Run rapid concept desirability tests.⁠ ▪️ All in a matter of minutes, not months.⁠ ⁠ 𝗛𝗮𝘃𝗲 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗛𝘂𝗺𝗮𝗻𝘀 𝗷𝗼𝗶𝗻 𝘆𝗼𝘂𝗿 𝗧𝗲𝗮𝗺:⁠ ▪️ Modeled on world-class innovators in product management, experience design, marketing, content strategy and more⁠ ▪️ They can be trained on past work to then collaborate with you on ground-breaking ideas.⁠ ▪️ Or work autonomously to simultaneously generate and validate new products and concepts.⁠ ⁠ Synthetic Humans give us the power to discover human insight, empathize, innovate and validate in revolutionary ways.⁠ ⁠ 𝗥𝗲𝗮𝗱𝘆 𝘁𝗼 𝗰𝗿𝗲𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗵𝘂𝗺𝗮𝗻𝘀?⁠ ⁠ Get started at

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗛𝘂𝗺𝗮𝗻𝘀™️ — trainable AI beings that transform the ways teams can research and innovate.⁠ ⁠ Each Synthetic Human is trained on real, human data to have a complex personality, modeled on over 100 attributes of the human psyche. Each human has long-term memory and the ability to see.⁠ ⁠ What can you do with them?⁠ ⁠ 𝗨𝘀𝗲 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗛𝘂𝗺𝗮𝗻𝘀 𝗳𝗼𝗿 𝗨𝘀𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵:⁠ ▪️ Securely mirror your existing and desired customers at global scale.⁠ ▪️ Then run both qualitative and quantitative research studies with high degrees of accuracy.⁠ ▪️ Build empathy directly with individuals.⁠ ▪️ Create research communities that remember and evolve.⁠ ▪️ Run rapid concept desirability tests.⁠ ▪️ All in a matter of minutes, not months.⁠ ⁠ 𝗛𝗮𝘃𝗲 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗛𝘂𝗺𝗮𝗻𝘀 𝗷𝗼𝗶𝗻 𝘆𝗼𝘂𝗿 𝗧𝗲𝗮𝗺:⁠ ▪️ Modeled on world-class innovators in product management, experience design, marketing, content strategy and more⁠ ▪️ They can be trained on past work to then collaborate with you on ground-breaking ideas.⁠ ▪️ Or work autonomously to simultaneously generate and validate new products and concepts.⁠ ⁠ Synthetic Humans give us the power to discover human insight, empathize, innovate and validate in revolutionary ways.⁠ ⁠ 𝗥𝗲𝗮𝗱𝘆 𝘁𝗼 𝗰𝗿𝗲𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗵𝘂𝗺𝗮𝗻𝘀?⁠ ⁠ Get started at

F Λ N T Λ S Y

12,376 görüntüleme • 2 yıl önce

🌍𝗔𝗳𝗿𝗶𝗰𝗮 𝗜𝘀 𝗡𝗼𝘁 𝗪𝗮𝗶𝘁𝗶𝗻𝗴 — 𝗜𝘁’𝘀 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲! Speaking at the Georgia State University Andrew Young School in the United States, during the MandelaWshFellowship, I carried with me the weight of responsibility and generational urgency for Africa’s future — 𝗮 𝗿𝗶𝘀𝗶𝗻𝗴 𝗰𝗼𝗻𝘁𝗶𝗻𝗲𝗻𝘁 𝘁𝗵𝗮𝘁 𝗶𝘀 𝗻𝗼𝘁 𝘄𝗮𝗶𝘁𝗶𝗻𝗴 𝘁𝗼 𝗯𝗲 𝗶𝗻𝘃𝗶𝘁𝗲𝗱 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗯𝘂𝘁 𝗶𝘀 𝗮𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝘀𝗵𝗮𝗽𝗶𝗻𝗴 𝗶𝘁. ◼️𝗧𝗼 𝗴𝗹𝗼𝗯𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀: The real ROI lies in co-creation. Africa is not just the next frontier — 𝗶𝘁 𝗶𝘀 𝘆𝗼𝘂𝗿 𝗶𝗻𝗱𝗶𝘀𝗽𝗲𝗻𝘀𝗮𝗯𝗹𝗲 𝗰𝗼-𝗮𝗿𝗰𝗵𝗶𝘁𝗲𝗰𝘁 𝗼𝗳 𝘁𝗵𝗲 𝟮𝟭𝘀𝘁 𝗰𝗲𝗻𝘁𝘂𝗿𝘆. From market stalls transforming into data hubs to farms evolving into predictive engines, young African pioneers are not only reimagining AI’s potential — they are engineering blueprints the world will follow. Partner with us. Invest in our talent pipelines. Scale our homegrown breakthroughs. 𝗧𝗵𝗮𝘁 𝗶𝘀 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗳𝗼𝗿𝗲𝘀𝗶𝗴𝗵𝘁. ◼️𝗧𝗼 𝗔𝗳𝗿𝗶𝗰𝗮’𝘀 𝗯𝘂𝗶𝗹𝗱𝗲𝗿𝘀: Your canvas is the world. Code with purpose. Build with vision. Lead with audacity. Scale your vision globally. The world isn’t waiting 𝗳𝗼𝗿 𝘆𝗼𝘂 —it’s waiting 𝗼𝗻 𝘆𝗼𝘂. Don’t catch up—leap ahead. Define what’s next. This is the future we are building at Otic Group. Our 𝗲𝘁𝗵𝗼𝘀 is simple: 𝗧𝗵𝗲 𝗺𝗼𝘀𝘁 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝘁, 𝗽𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗶𝗻 𝘂𝘀. Our work isn't about importing solutions; it's about unlocking that innate brilliance. Do that, and you don't just change a market—you change the century!

🌍𝗔𝗳𝗿𝗶𝗰𝗮 𝗜𝘀 𝗡𝗼𝘁 𝗪𝗮𝗶𝘁𝗶𝗻𝗴 — 𝗜𝘁’𝘀 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲! Speaking at the Georgia State University Andrew Young School in the United States, during the MandelaWshFellowship, I carried with me the weight of responsibility and generational urgency for Africa’s future — 𝗮 𝗿𝗶𝘀𝗶𝗻𝗴 𝗰𝗼𝗻𝘁𝗶𝗻𝗲𝗻𝘁 𝘁𝗵𝗮𝘁 𝗶𝘀 𝗻𝗼𝘁 𝘄𝗮𝗶𝘁𝗶𝗻𝗴 𝘁𝗼 𝗯𝗲 𝗶𝗻𝘃𝗶𝘁𝗲𝗱 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗯𝘂𝘁 𝗶𝘀 𝗮𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝘀𝗵𝗮𝗽𝗶𝗻𝗴 𝗶𝘁. ◼️𝗧𝗼 𝗴𝗹𝗼𝗯𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀: The real ROI lies in co-creation. Africa is not just the next frontier — 𝗶𝘁 𝗶𝘀 𝘆𝗼𝘂𝗿 𝗶𝗻𝗱𝗶𝘀𝗽𝗲𝗻𝘀𝗮𝗯𝗹𝗲 𝗰𝗼-𝗮𝗿𝗰𝗵𝗶𝘁𝗲𝗰𝘁 𝗼𝗳 𝘁𝗵𝗲 𝟮𝟭𝘀𝘁 𝗰𝗲𝗻𝘁𝘂𝗿𝘆. From market stalls transforming into data hubs to farms evolving into predictive engines, young African pioneers are not only reimagining AI’s potential — they are engineering blueprints the world will follow. Partner with us. Invest in our talent pipelines. Scale our homegrown breakthroughs. 𝗧𝗵𝗮𝘁 𝗶𝘀 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗳𝗼𝗿𝗲𝘀𝗶𝗴𝗵𝘁. ◼️𝗧𝗼 𝗔𝗳𝗿𝗶𝗰𝗮’𝘀 𝗯𝘂𝗶𝗹𝗱𝗲𝗿𝘀: Your canvas is the world. Code with purpose. Build with vision. Lead with audacity. Scale your vision globally. The world isn’t waiting 𝗳𝗼𝗿 𝘆𝗼𝘂 —it’s waiting 𝗼𝗻 𝘆𝗼𝘂. Don’t catch up—leap ahead. Define what’s next. This is the future we are building at Otic Group. Our 𝗲𝘁𝗵𝗼𝘀 is simple: 𝗧𝗵𝗲 𝗺𝗼𝘀𝘁 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝘁, 𝗽𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗶𝗻 𝘂𝘀. Our work isn't about importing solutions; it's about unlocking that innate brilliance. Do that, and you don't just change a market—you change the century!

Nesta Paul Katende

167,546 görüntüleme • 1 yıl önce

𝗜𝘁'𝘀 𝘁𝗶𝗺𝗲 𝗳𝗼𝗿 𝘂𝘀 𝘁𝗼 𝗰𝗼𝗺𝗲 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿: 𝗜𝘁'𝘀 𝘁𝗵𝗲 𝗼𝗻𝗹𝘆 𝘄𝗮𝘆 𝘁𝗵𝗮𝘁 𝘁𝗵𝗶𝗻𝗴𝘀 𝘄𝗶𝗹𝗹 𝗴𝗲𝘁 𝗯𝗲𝘁𝘁𝗲𝗿: 𝗜𝘁'𝘀 𝘁𝗶𝗺𝗲 𝗳𝗼𝗿 𝘂𝘀 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗮 𝘀𝘁𝗮𝗻𝗱: 𝗦𝗼 𝗰𝗼𝗺𝗲 𝗼𝗻, please 𝗹𝗲𝗻𝗱 𝗮 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝗵𝗮𝗻𝗱, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗱𝗼𝗻𝗮𝘁𝗲, 𝘁𝘂𝗿𝗻 𝗼𝗻 𝗼𝘂𝗿 𝗻𝗼𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻, and help 𝗿𝗲𝗽𝗼𝘀𝘁 𝗼𝘂𝗿 𝘁𝘄𝗲𝗲𝘁𝘀 𝗮𝗻𝘆𝘄𝗵𝗲𝗿𝗲, 𝗼𝗿 𝗮𝗻𝘆𝘁𝗶𝗺𝗲 𝘆𝗼𝘂 𝘀𝗲𝗲 𝗶𝘁 𝗼𝗻 𝘆𝗼𝘂𝗿 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲 Kindly donate to our Ramadan Feeding Project 🙏 or please help retweet this ₦𝗮𝗶𝗿𝗮 𝗔𝗰𝗰𝗼𝘂𝗻𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: 2035844969 First Bank Feed the Vulnerable Families in [Nigeria} Foundation 𝗚𝗼𝗳𝘂𝗻𝗱𝗺𝗲: 𝗣𝗮𝘆𝘀𝘁𝗮𝗰𝗸: We all have the ability to be the reason struggling widows, orphans, displaced families, street dwellers, individuals with special needs, families affected by insecurity, and individuals in distress smiles during the blessed month of Ramadan. Together, we can mobilize change and work together to end hunger in our community and across Nigeria. Kindly donate and please help retweet 🙏 Toyyib Adewale Adelodun IamAbdul_👳🏾‍♂️ HAKEEM ❤️AyEsHaH🤍🌟🌻 𝐂𝐡𝐞𝐟𝐳𝐚𝐫𝐚𝐡(𝐌𝐫𝐬)💍🦋 Abdul-Muizz (Realtor) Khadijah🍒 FS Yusuf BASH-AAR 🔞 FAREEDA KIRI🌹🌹🌹🌹 Faridah🩵 Fareedah Abdul Hunaida Tasleemah (Abuja Baker) Khalil Mai hula Jr🇳🇬🇵🇸 @CallMeMassimo Mrs Zanga🔥❣️ Fatimah The Fabric Vendor. Nigga Snow Fawaz Okanlawon Rukksss🍯💜 FFS 🧕🏽💜💙 SM Anas

𝗜𝘁'𝘀 𝘁𝗶𝗺𝗲 𝗳𝗼𝗿 𝘂𝘀 𝘁𝗼 𝗰𝗼𝗺𝗲 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿: 𝗜𝘁'𝘀 𝘁𝗵𝗲 𝗼𝗻𝗹𝘆 𝘄𝗮𝘆 𝘁𝗵𝗮𝘁 𝘁𝗵𝗶𝗻𝗴𝘀 𝘄𝗶𝗹𝗹 𝗴𝗲𝘁 𝗯𝗲𝘁𝘁𝗲𝗿: 𝗜𝘁'𝘀 𝘁𝗶𝗺𝗲 𝗳𝗼𝗿 𝘂𝘀 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗮 𝘀𝘁𝗮𝗻𝗱: 𝗦𝗼 𝗰𝗼𝗺𝗲 𝗼𝗻, please 𝗹𝗲𝗻𝗱 𝗮 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝗵𝗮𝗻𝗱, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗱𝗼𝗻𝗮𝘁𝗲, 𝘁𝘂𝗿𝗻 𝗼𝗻 𝗼𝘂𝗿 𝗻𝗼𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻, and help 𝗿𝗲𝗽𝗼𝘀𝘁 𝗼𝘂𝗿 𝘁𝘄𝗲𝗲𝘁𝘀 𝗮𝗻𝘆𝘄𝗵𝗲𝗿𝗲, 𝗼𝗿 𝗮𝗻𝘆𝘁𝗶𝗺𝗲 𝘆𝗼𝘂 𝘀𝗲𝗲 𝗶𝘁 𝗼𝗻 𝘆𝗼𝘂𝗿 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲 Kindly donate to our Ramadan Feeding Project 🙏 or please help retweet this ₦𝗮𝗶𝗿𝗮 𝗔𝗰𝗰𝗼𝘂𝗻𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: 2035844969 First Bank Feed the Vulnerable Families in [Nigeria} Foundation 𝗚𝗼𝗳𝘂𝗻𝗱𝗺𝗲: 𝗣𝗮𝘆𝘀𝘁𝗮𝗰𝗸: We all have the ability to be the reason struggling widows, orphans, displaced families, street dwellers, individuals with special needs, families affected by insecurity, and individuals in distress smiles during the blessed month of Ramadan. Together, we can mobilize change and work together to end hunger in our community and across Nigeria. Kindly donate and please help retweet 🙏 Toyyib Adewale Adelodun IamAbdul_👳🏾‍♂️ HAKEEM ❤️AyEsHaH🤍🌟🌻 𝐂𝐡𝐞𝐟𝐳𝐚𝐫𝐚𝐡(𝐌𝐫𝐬)💍🦋 Abdul-Muizz (Realtor) Khadijah🍒 FS Yusuf BASH-AAR 🔞 FAREEDA KIRI🌹🌹🌹🌹 Faridah🩵 Fareedah Abdul Hunaida Tasleemah (Abuja Baker) Khalil Mai hula Jr🇳🇬🇵🇸 @CallMeMassimo Mrs Zanga🔥❣️ Fatimah The Fabric Vendor. Nigga Snow Fawaz Okanlawon Rukksss🍯💜 FFS 🧕🏽💜💙 SM Anas

FTVF Foundation

25,483 görüntüleme • 2 yıl önce

"𝗧𝗿𝘂𝗹𝘆, 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗮𝗶𝗻𝗳𝘂𝗹 𝘁𝗲𝗮𝗿𝘀 𝘄𝗲 𝗰𝗿𝘆 𝗮𝗿𝗲 𝘁𝗵𝗼𝘀𝗲 𝘄𝗲 𝗰𝗿𝘆 𝗶𝗻 𝘀𝗶𝗹𝗲𝗻𝗰𝗲," 𝗽𝗹𝗲𝗮𝘀𝗲 𝗶𝗳 𝘁𝗵𝗶𝘀 𝗽𝗼𝗽𝘀 𝘂𝗽 𝗼𝗻 𝘆𝗼𝘂𝗿 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲, 𝗸𝗶𝗻𝗱𝗹𝘆 𝗱𝗼𝗻𝗮𝘁𝗲 𝗮 𝘁𝗼𝗸𝗲𝗻 𝗶𝗳 𝘆𝗼𝘂 𝗰𝗮𝗻, 𝗮𝗻𝗱 𝗶𝗳 𝘆𝗼𝘂 𝗮𝗿𝗲 𝘂𝗻𝗮𝗯𝗹𝗲 𝘁𝗼 𝗱𝗼𝗻𝗮𝘁𝗲, 𝗸𝗶𝗻𝗱𝗹𝘆 𝗵𝗲𝗹𝗽 𝗿𝗲𝘁𝘄𝗲𝗲𝘁 𝘁𝗵𝗶𝘀. ₦𝗮𝗶𝗿𝗮 𝗔𝗰𝗰𝗼𝘂𝗻𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: 𝗙𝗶𝗿𝘀𝘁 𝗕𝗮𝗻𝗸 𝟮𝟬𝟯𝟱𝟴𝟰𝟰𝟵𝟲𝟵 𝗙𝗲𝗲𝗱 𝘁𝗵𝗲 𝗩𝘂𝗹𝗻𝗲𝗿𝗮𝗯𝗹𝗲 𝗙𝗮𝗺𝗶𝗹𝗶𝗲𝘀 𝗶𝗻 𝗡𝗶𝗴𝗲𝗿𝗶𝗮 𝗙𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 Donation Link: 𝗬𝗼𝘂𝗿 ₦𝟱𝟬𝟬, ₦𝟭,𝟬𝟬𝟬, ₦𝟭𝟬,𝟬𝟬𝟬, ₦𝟭𝟬𝟬,𝟬𝟬𝟬 𝗼𝗿 𝗺𝗼𝗿𝗲 𝘄𝗶𝗹𝗹 𝗽𝗿𝗼𝘃𝗶𝗱𝗲 𝗿𝗲𝗹𝗶𝗲𝗳 𝗮𝗻𝗱 𝗺𝗲𝗮𝗹𝘀 𝗳𝗼𝗿 𝗸𝗶𝗱𝘀 𝗮𝗻𝗱 𝗮𝗱𝘂𝗹𝘁𝘀 𝗹𝗶𝘃𝗶𝗻𝗴 𝗶𝗻 𝗟𝗲𝗽𝗿𝗼𝘀𝘆. 𝗪𝗲 𝘄𝗼𝘂𝗹𝗱 𝗮𝗹𝘀𝗼 𝗯𝗲 𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝘁𝗼 𝗽𝗿𝗼𝗳𝗶𝗹𝗲 𝘁𝗵𝗲𝗶𝗿 𝗸𝗶𝗱𝘀 𝗮𝗻𝗱 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗵𝗲𝘆 𝗮𝗿𝗲 𝗮𝗹𝗹 𝗲𝗻𝗿𝗼𝗹𝗹𝗲𝗱 𝗶𝗻 𝗮 𝘃𝗲𝗿𝘆 𝗴𝗼𝗼𝗱 𝘀𝗰𝗵𝗼𝗼𝗹. 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝘄𝗲 𝗰𝗮𝗻 𝗵𝗲𝗹𝗽 𝘁𝗵𝗲𝗶𝗿 𝗽𝗮𝗿𝗲𝗻𝘁𝘀 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝘁𝗵𝗶𝘀 𝗹𝗶𝗳𝗲𝗹𝗼𝗻𝗴 𝗱𝗿𝗲𝗮𝗺 Adedimeji Lateef Shakirah TheRemmySaheed 😏 Akanni of Ogun | Mobile Grapher 📽️📱 6’2ft Abubakar Sidiq Usman Ayo of Ibadan YourMe 👨🏿‍🔧 Luqman_أونيوى 🇳🇬 🇵🇸 MO Dee_Dee❤️ SALAWU||OMOIYAONIPAKO Ibrahim Kazeem, MBA. 𝑰𝒅𝒓𝒊𝒔 𝑨. 𝑶𝒏𝒊 PhD Emerald 💚 هداية Inside Ilorin NG 🇳🇬 Abeni Okin🦚❤️ Hafeezah ❤️ pappi ♛, your designer Hon. Arinola Lawal Folarin Muize | 👞🤝 Ibrahim Ibrahim BIG-T 👨‍💻📷 Eniola Kunle Sulyman - Yusuf Asiya nomad 👑 Hassanat_lifestyle Olówó Èkó | Mo yọ̀ fún ẹ, mo yọ̀ fún ara mi Fatteh Hamid, MON OLUWATOSIN ✨ @Asakeofoyo HAKEEM osita popcorn Inside Òṣogbo Hashim Ibrahim-Bolaji 📊📉📈 BIRCHI 👑 Pharaoh 👑 Cool_Ustaaz ☪ H’s mom Danjuma Aliagan, PhD 🔴AMINULLAH حبيبي 💛 🤍 𝓣𝓱𝓪𝓽 𝓨𝓸𝓻𝓾𝓫𝓪 𝓗𝓲𝓳𝓪𝓫𝓼𝓽𝓮𝓻😎💛 Duchess_Beeyah🖤🤍 Justsophie_🌹❤️ 👑S.A.L.A.K.O🕊 Sisi Jetue Abubakr Aproko Doctor Global @EtuboDragon Renè The Leader ❤

"𝗧𝗿𝘂𝗹𝘆, 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗮𝗶𝗻𝗳𝘂𝗹 𝘁𝗲𝗮𝗿𝘀 𝘄𝗲 𝗰𝗿𝘆 𝗮𝗿𝗲 𝘁𝗵𝗼𝘀𝗲 𝘄𝗲 𝗰𝗿𝘆 𝗶𝗻 𝘀𝗶𝗹𝗲𝗻𝗰𝗲," 𝗽𝗹𝗲𝗮𝘀𝗲 𝗶𝗳 𝘁𝗵𝗶𝘀 𝗽𝗼𝗽𝘀 𝘂𝗽 𝗼𝗻 𝘆𝗼𝘂𝗿 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲, 𝗸𝗶𝗻𝗱𝗹𝘆 𝗱𝗼𝗻𝗮𝘁𝗲 𝗮 𝘁𝗼𝗸𝗲𝗻 𝗶𝗳 𝘆𝗼𝘂 𝗰𝗮𝗻, 𝗮𝗻𝗱 𝗶𝗳 𝘆𝗼𝘂 𝗮𝗿𝗲 𝘂𝗻𝗮𝗯𝗹𝗲 𝘁𝗼 𝗱𝗼𝗻𝗮𝘁𝗲, 𝗸𝗶𝗻𝗱𝗹𝘆 𝗵𝗲𝗹𝗽 𝗿𝗲𝘁𝘄𝗲𝗲𝘁 𝘁𝗵𝗶𝘀. ₦𝗮𝗶𝗿𝗮 𝗔𝗰𝗰𝗼𝘂𝗻𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: 𝗙𝗶𝗿𝘀𝘁 𝗕𝗮𝗻𝗸 𝟮𝟬𝟯𝟱𝟴𝟰𝟰𝟵𝟲𝟵 𝗙𝗲𝗲𝗱 𝘁𝗵𝗲 𝗩𝘂𝗹𝗻𝗲𝗿𝗮𝗯𝗹𝗲 𝗙𝗮𝗺𝗶𝗹𝗶𝗲𝘀 𝗶𝗻 𝗡𝗶𝗴𝗲𝗿𝗶𝗮 𝗙𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 Donation Link: 𝗬𝗼𝘂𝗿 ₦𝟱𝟬𝟬, ₦𝟭,𝟬𝟬𝟬, ₦𝟭𝟬,𝟬𝟬𝟬, ₦𝟭𝟬𝟬,𝟬𝟬𝟬 𝗼𝗿 𝗺𝗼𝗿𝗲 𝘄𝗶𝗹𝗹 𝗽𝗿𝗼𝘃𝗶𝗱𝗲 𝗿𝗲𝗹𝗶𝗲𝗳 𝗮𝗻𝗱 𝗺𝗲𝗮𝗹𝘀 𝗳𝗼𝗿 𝗸𝗶𝗱𝘀 𝗮𝗻𝗱 𝗮𝗱𝘂𝗹𝘁𝘀 𝗹𝗶𝘃𝗶𝗻𝗴 𝗶𝗻 𝗟𝗲𝗽𝗿𝗼𝘀𝘆. 𝗪𝗲 𝘄𝗼𝘂𝗹𝗱 𝗮𝗹𝘀𝗼 𝗯𝗲 𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝘁𝗼 𝗽𝗿𝗼𝗳𝗶𝗹𝗲 𝘁𝗵𝗲𝗶𝗿 𝗸𝗶𝗱𝘀 𝗮𝗻𝗱 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗵𝗲𝘆 𝗮𝗿𝗲 𝗮𝗹𝗹 𝗲𝗻𝗿𝗼𝗹𝗹𝗲𝗱 𝗶𝗻 𝗮 𝘃𝗲𝗿𝘆 𝗴𝗼𝗼𝗱 𝘀𝗰𝗵𝗼𝗼𝗹. 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝘄𝗲 𝗰𝗮𝗻 𝗵𝗲𝗹𝗽 𝘁𝗵𝗲𝗶𝗿 𝗽𝗮𝗿𝗲𝗻𝘁𝘀 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝘁𝗵𝗶𝘀 𝗹𝗶𝗳𝗲𝗹𝗼𝗻𝗴 𝗱𝗿𝗲𝗮𝗺 Adedimeji Lateef Shakirah TheRemmySaheed 😏 Akanni of Ogun | Mobile Grapher 📽️📱 6’2ft Abubakar Sidiq Usman Ayo of Ibadan YourMe 👨🏿‍🔧 Luqman_أونيوى 🇳🇬 🇵🇸 MO Dee_Dee❤️ SALAWU||OMOIYAONIPAKO Ibrahim Kazeem, MBA. 𝑰𝒅𝒓𝒊𝒔 𝑨. 𝑶𝒏𝒊 PhD Emerald 💚 هداية Inside Ilorin NG 🇳🇬 Abeni Okin🦚❤️ Hafeezah ❤️ pappi ♛, your designer Hon. Arinola Lawal Folarin Muize | 👞🤝 Ibrahim Ibrahim BIG-T 👨‍💻📷 Eniola Kunle Sulyman - Yusuf Asiya nomad 👑 Hassanat_lifestyle Olówó Èkó | Mo yọ̀ fún ẹ, mo yọ̀ fún ara mi Fatteh Hamid, MON OLUWATOSIN ✨ @Asakeofoyo HAKEEM osita popcorn Inside Òṣogbo Hashim Ibrahim-Bolaji 📊📉📈 BIRCHI 👑 Pharaoh 👑 Cool_Ustaaz ☪ H’s mom Danjuma Aliagan, PhD 🔴AMINULLAH حبيبي 💛 🤍 𝓣𝓱𝓪𝓽 𝓨𝓸𝓻𝓾𝓫𝓪 𝓗𝓲𝓳𝓪𝓫𝓼𝓽𝓮𝓻😎💛 Duchess_Beeyah🖤🤍 Justsophie_🌹❤️ 👑S.A.L.A.K.O🕊 Sisi Jetue Abubakr Aproko Doctor Global @EtuboDragon Renè The Leader ❤

FTVF Foundation

105,139 görüntüleme • 2 yıl önce

$NWBO #𝗗𝗖𝗩𝗮𝘅-𝗟: 𝗧𝗵𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗶𝗻 𝗣𝗹𝗮𝗶𝗻 𝗧𝗲𝗿𝗺𝘀 A short, plain-language reading of the survival evidence for DCVax-L in #glioblastoma, and what it means under the MHRAgovuk guideline on external control arms. 📊 𝗣𝗔𝗥𝗧 𝗢𝗡𝗘: 𝗪𝗛𝗔𝗧 𝗧𝗛𝗘 𝗧𝗥𝗜𝗔𝗟 𝗙𝗢𝗨𝗡𝗗, 𝗔𝗡𝗗 𝗪𝗛𝗬 𝗜𝗧 𝗠𝗔𝗧𝗧𝗘𝗥𝗦 DCVax-L more than doubled five-year survival, and the benefit is durability: a subset gets lasting disease control and simply stays alive. 💉 𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝗱𝗿𝘂𝗴 𝗶𝘀 DCVax-L is a personalized cancer vaccine for glioblastoma, the deadliest form of brain cancer and a designated orphan disease. It is a living drug: its active ingredient is the patient's own immune cells, primed with proteins from that patient's surgically removed tumor, so the immune system learns to attack the cancer. Unlike a chemical drug that is metabolized and cleared, it switches on a living immune response that keeps working long after the injection. Glioblastoma comes back in almost everyone: even with the full standard of surgery, radiation, and temozolomide chemotherapy, most patients live under two years, and only about one in twenty reaches five. DCVax-L is given on top of that standard care, not in place of it: every patient in the trial received surgery, radiation, and temozolomide, and the vaccine was added to it, so the comparison measures what the vaccine adds. For two decades, nearly every new drug tried in this disease has failed. That is the backdrop against which any positive result must be judged. 📈 𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 𝗳𝗼𝘂𝗻𝗱 In a Phase 3 trial of 331 patients, those who received DCVax-L lived longer. At the median the gain looks modest, about three months (19.3 versus 16.5). The number that matters sits at the far end of the survival curve: more than twice as many vaccine patients were alive at five years, 13.0% versus 5.7%, and a few reached ten years in a disease that usually kills within three. In patients whose tumor had already returned, the effect was larger still, cutting the risk of death by about 42%. 👥 𝗘𝘃𝗲𝗿𝘆 𝗴𝗿𝗼𝘂𝗽 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝗲𝗱, 𝗲𝘃𝗲𝗻 𝘁𝗵𝗲 𝗵𝗮𝗿𝗱𝗲𝘀𝘁 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁 The benefit was not confined to the easy cases. Of the six prespecified subgroups the trial examined, every single one favored DCVax-L, and there was no group in which it did worse than standard care. The largest gains came in patients whose tumors carry MGMT methylation, who reached a median survival of 30.2 months from randomization against 21.3 for the controls. But even the hardest-to-treat patients, whose tumors lack that methylation, resist standard chemotherapy, and carry the worst prognosis in this disease, still came out ahead with the vaccine, at a hazard ratio of 0.93. A treatment that helps across the whole population, and helps most where the biology is most favorable, is acting like a real drug. 📉 𝗪𝗵𝘆 𝘁𝗵𝗲 𝗺𝗲𝗱𝗶𝗮𝗻 𝗵𝗶𝗱𝗲𝘀 𝘁𝗵𝗲 𝗿𝗲𝗮𝗹 𝘀𝘁𝗼𝗿𝘆 That five-year number is the whole story, and the median buries it. Almost every treatment that ever helped in glioblastoma did the same modest thing: it slid the survival curve a few months to the right, then let it fall back. Doubling five-year survival is different in kind. A three-month gain at the median cannot, by itself, double the fraction alive at five years. The only shape that produces both numbers is a split: most patients get the small delay the median measures, while a subset gets durable disease control that lasts for years, well past where glioblastoma should have ended them. That subset is the long tail of the curve, and it is where the benefit lives. A median ignores extremes, the way a town's median income tells you nothing about its millionaires. The real story is not a longer delay; it is that a meaningful share of patients simply stay alive. 🧬 𝗪𝗵𝘆 𝘁𝗵𝗲 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗽𝗿𝗲𝗱𝗶𝗰𝘁𝘀 𝘁𝗵𝗶𝘀 𝘀𝗵𝗮𝗽𝗲 The tail is not luck. It is what this biology is built to produce. The vaccine carries proteins from the patient's own tumor, so it aims the immune system at whatever that tumor is made of, not a fixed short list of targets. And it amplifies: one trained immune cell drives many others that multiply into cancer-killers. Andres Salazar, the neurologist who developed poly-ICLC into the clinical adjuvant given with the vaccine, puts it in a line: you start the fire, and you keep it burning. A response like that does not produce a one-time bump. It builds and widens over time. What matters is not just that a response forms, but what kind. Dendritic cells are the immune system's master switch for that, the cells that set what kind of attack the body mounts, and this vaccine is built from them. It drives what immunologists call a type 1 polarized response: an interferon-driven, cytotoxic program aimed squarely at the tumor. That direction comes from the vaccine itself; the poly-ICLC adjuvant given with it drives the same interferon program and sustains it. That is the active ingredient, and it has been measured. In UCLA studies of this approach, the patients whose immune systems mounted the strongest interferon response lived the longest. The response also spreads. In a different cancer, a vaccine carried on this same poly-ICLC adjuvant drove more than 70% of a patient's cancer-killing T cells to target proteins that were never in the vaccine: the immune system outgrew its original targets and went after the rest of the tumor on its own. This is called epitope spreading, and it is not particular to one tumor; it is what this kind of response does, and it is the kind of response DCVax-L builds. That breadth is the likeliest thing separating the long-term survivors from everyone else, a response that breaks past its targets and clears the disease rather than one that stays caged and stops. There is even a tell in who benefits most: the effect is largest in tumors whose biology builds up more mutations under chemotherapy, and more mutations mean more targets for a whole-tumor vaccine to find. The same logic explains what the vaccine is not, and what it does not need. Checkpoint inhibitors, the drugs that release the immune system's brakes, have failed on their own in glioblastoma because there was no active response to release; the vaccine supplies that response first. That makes the vaccine the natural foundation for combination therapy. Combining it with its poly-ICLC adjuvant, made by Oncovir, has already shown meaningful survival gains in a published analysis. In the pivotal trial, the vaccine's proven benefit came added on top of standard chemotherapy and radiation; the newer question is how much the immune response can carry on its own. A UCLA trial is now testing that in patients whose tumors have returned, adding #Keytruda (pembrolizumab), the checkpoint antibody from $MRK, in a regimen built entirely around the immune response with no chemotherapy or radiation in it at all. Its interim survival curve shows the shape the biology predicts. In the arm given the vaccine and Keytruda together after surgery, the curve does not fall away but flattens into a plateau, with roughly 65% of patients still alive well past the point where recurrent glioblastoma kills nearly everyone. That plateau is the signature of a response that took hold and lasted, the type 1 attack forming durable immune memory so that once the disease is controlled it stays controlled. That is where this points, and where it is already arriving, a treatment that works through the response itself, one that could in time lean less on the harsh radiation and chemotherapy that have defined glioblastoma care and barely moved its survival. These are interim results, from Prins, Cloughesy, and Liau at UCLA. 🔍 𝗣𝗔𝗥𝗧 𝗧𝗪𝗢: 𝗜𝗦 𝗜𝗧 𝗥𝗘𝗔𝗟? The trial was randomized, an independent experiment shows the outside comparison is trustworthy, and every separate check points the same way. 🤔 𝗧𝗵𝗲 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝘄𝗵𝘆 𝗶𝘁 𝗺𝗶𝘀𝘀𝗲𝘀 𝘁𝗵𝗲 𝗺𝗮𝗿𝗸 So much for what happened; the harder question is whether to believe it. The trial has the feature critics attacked: it could not keep a normal placebo group, because patients assigned to placebo were allowed, by design and by medical ethics, to switch to the vaccine once their cancer returned, and almost all did. That erased the internal comparison, so survival was measured against closely matched patients from other completed trials, an approach called an external control, which critics argued could tilt toward the vaccine. What the objection misses is where the randomization went. This was a randomized, blinded trial. The patients who got the vaccine were assigned to it at random, not hand-picked, so the treated group is an ordinary slice of the trial population, not a favorable one. The crossover removed the placebo group but never touched how patients were assigned. That leaves exactly one place for bias to enter, the outside comparison group, which is precisely what the next checks test. ✅ 𝗧𝗵𝗲 𝗰𝗵𝗲𝗰𝗸 𝘁𝗵𝗮𝘁 𝗺𝗮𝗸𝗲𝘀 𝗶𝘁 𝘁𝗿𝘂𝘀𝘁𝘄𝗼𝗿𝘁𝗵𝘆 Before trusting a scale to weigh something unknown, you confirm it reads zero with nothing on it. That is what the calibration does, and it is the strongest part of the case. A separate, independent randomized trial called INSIGhT was run through the very same external-control method, and it gave two answers. First, three experimental drugs that had already failed were run through it, and it correctly found nothing (hazard ratios of 1.00, 0.93, and 0.88): the method does not manufacture a benefit where none exists. Second, INSIGhT's external controls were set head to head against its own randomized internal controls, and they were statistically indistinguishable. In this disease, an external control reproduces the answer a real randomized control would have given, and because that trial belonged to a different group, no one can say a sponsor graded its own work. The one place bias could enter, the control side, is the one place an independent randomized experiment certified as clean. There is a deeper fit worth naming, and it is what makes the two halves of this case one. The same instrument that reported those three failures as failures reads the vaccine as a success, and the biology says why: those drugs could not hold a tumor this varied, and the vaccine builds the broad, lasting response that finally does. One method, opposite readings, and one mechanism behind both. The statistics and the biology are not two arguments. They are the same argument seen twice. 🃏 𝗪𝗮𝘀 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻 𝘀𝘁𝗮𝗰𝗸𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘃𝗮𝗰𝗰𝗶𝗻𝗲'𝘀 𝗳𝗮𝘃𝗼𝗿? A natural worry is that the outside comparison was arranged after the fact to flatter the vaccine. The trial was built to prevent that. The patients to compare against, and the rules for matching them, were fixed in writing before anyone saw results, and an independent firm, not the company, chose the comparison trials against those rules. The trial also switched its main measure partway through, from delaying tumor growth to overall survival, but that was not a maneuver: immune treatments cause a harmless swelling that mimics tumor growth on scans and made the growth measure unreliable, and the switch was made while everyone was still blinded. Three further checks point the same way. Survival in this disease has not improved over the years the comparison spans, so same-era controls are sound. When the borrowed controls were tested directly, the comparison came out conservative rather than flattering. And the controls were counted from the same point in the disease as the vaccine patients, so neither side got a head start. Where the comparison can err, it errs against the drug. 🔬 𝗧𝗵𝗲 𝗺𝗼𝗿𝗲 𝗰𝗮𝗿𝗲𝗳𝘂𝗹 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗺𝗮𝗱𝗲 𝘁𝗵𝗲 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗯𝗶𝗴𝗴𝗲𝗿, 𝗻𝗼𝘁 𝘀𝗺𝗮𝗹𝗹𝗲𝗿 The first comparison used whole groups. A sharper one became possible once patient-level records from three other trials could be obtained, pairing each vaccine patient with controls matched on the traits that drive survival in glioblastoma, above all MGMT methylation status, matched exactly, plus age, sex, extent of surgery, residual disease, and performance status. When the comparison got sharper, the benefit grew in every one of these analyses. The original cohort-level estimate was 2.8 months. Patient-level matching across the three trials put the gain between 3.4 and 6.3 months, and a method that weights patients rather than pairing them put it between 3.4 and 4.3, with several of the matched comparisons roughly doubling the original figure. The hazard ratio moved the same way, from 0.80 to between 0.69 and 0.77. The direction matters. A real effect blurred by crude matching gets clearer when the matching improves, while a biased one tends to shrink. It got stronger. 🕵️ 𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗵𝗶𝗱𝗱𝗲𝗻 𝗯𝗶𝗮𝘀 𝘄𝗼𝘂𝗹𝗱 𝗶𝘁 𝘁𝗮𝗸𝗲 𝘁𝗼 𝗲𝘅𝗽𝗹𝗮𝗶𝗻 𝘁𝗵𝗶𝘀 𝗮𝘄𝗮𝘆 A fair question is how much hidden bias it would take to erase the result. Statisticians measure that with the E-value, and here a hidden factor would have to be about as strong as age is on survival, would also have to drive who received the vaccine, and would have to have escaped the decades of research that mapped every known risk factor in this disease. A second, independent check, Rosenbaum's Gamma, comes at it from the other side, asking how large an unseen imbalance between matched patients it would take to break the result, and it reaches the same verdict. Every factor strong enough to matter was already matched. A hidden one that clears that bar is not plausible. 🔒 𝗪𝗵𝘆 𝘁𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁 𝗶𝘀 𝗵𝗮𝗿𝗱 𝘁𝗼 𝗳𝗮𝗸𝗲 The strongest point is not any single result. It is that a hidden bias big enough to explain the effect away would have to produce the same answer in every independent test at once: • The independent randomized calibration trial. • Three separate comparison trials, drawn from different studies. • Two different statistical methods that handle the data in different ways. • A separate pooled analysis of other dendritic-cell vaccine trials. • The internal math of the survival curve, which points to the same result (about 0.71 at five years) that the patient matching found. And it would have to fall in the exact direction the biology predicted before any data existed: a slow, widening benefit concentrated in long-term survivors. A single hidden factor that could forge all of that at once is not a hidden factor. It is a coincidence that does not happen. 🩺 𝗣𝗔𝗥𝗧 𝗧𝗛𝗥𝗘𝗘: 𝗪𝗛𝗔𝗧 𝗜𝗧 𝗠𝗘𝗔𝗡𝗦 The drug is nearly free of harm, the evidence fits an established and approved regulatory path, and what remains unrun changes nothing about the case. 🛡️ 𝗧𝗵𝗲 𝘀𝗮𝗳𝗲𝘁𝘆 Two things decide whether a real effect reaches patients: whether the drug is safe enough to use, and whether regulators will accept the evidence. The first is settled. Across 2,151 doses, only five serious side effects were even possibly related to the vaccine, with no autoimmunity and no cytokine storm. It is made once, in about eight days, then stored and given as a simple injection. When a treatment barely harms, the benefit needed to justify it falls, and the benefit here clears that lower bar easily. ⏳ 𝗪𝗵𝘆 𝘁𝗵𝗲 𝘀𝘁𝗿𝗼𝗻𝗴𝗲𝗿 𝗱𝗮𝘁𝗮 𝗮𝗽𝗽𝗲𝗮𝗿𝗲𝗱 𝗼𝗻𝗹𝘆 𝗻𝗼𝘄 A reasonable person asks why the sharper analysis appeared in 2026 and not in 2023. The answer is access, not choice. The patient-level analysis was written into the trial's plan from the start, to run if and when the data could be obtained. The company tried and could not get it in 2023, because the trials that held it had not released it; it became available later through a data-sharing repository, on the data owners' timeline, not the company's. The stronger analysis was always the plan. It was waiting on data that other parties control. 🔄 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗵𝗼𝘀𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘁𝘂𝗿𝗻𝗲𝗱 𝗮𝗹𝘀𝗼 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝗲𝗱 The vaccine helped not only newly diagnosed patients but also those whose tumor had already come back, and there the effect was the largest seen anywhere in the trial. In that group, median survival ran 13.2 months from recurrence against 7.8 for the controls. The separation opened immediately, with 90.6% of vaccine patients alive at six months against 64.0% of controls, and the lead held to the later marks, where survival more than doubled: 20.7% against 9.6% at two years, 11.1% against 5.1% at two and a half. These are the original cohort-level results, already published. The high-resolution patient-level matching that was applied to the newly diagnosed group has not yet been done here, for a practical reason: it needs patient records from other recurrent-cancer trials, held by a European research organization that shares them through its own formal request. Obtaining them is a routine next step, not an obstacle, and the newly diagnosed experience suggests the sharper analysis would only make the recurrent result stronger. The approval case rests on the newly diagnosed evidence, so nothing important depends on this step; it would simply sharpen a result that is already the strongest in the trial. 🏛️ 𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 Regulators do not treat an external control as a first choice, but the MHRA's guideline allows it in exactly this situation: a severe disease where a placebo trial is not ethical or feasible, and an effect large enough to interpret despite the design. The guideline even gives its own worked example of an acceptable external control, and it reads almost like a description of this trial: a rare disease, no ethical placebo, same-era standard-of-care controls, an objective survival endpoint, and an effect too large to blame on bias. DCVax-L fits on every count, and it was the first medicine ever to receive the MHRA's Promising Innovative Medicine designation, which asks essentially the same questions. The newly diagnosed case carries the decision on its own evidence, and regulators weigh that evidence against the disease it treats: in a cancer this lethal, with nothing better on offer, the question is whether the benefit is large, clear, and consistent enough to act on, and a benefit of this size, pointing the same way from every direction, is. 📜 𝗧𝗵𝗶𝘀 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗱𝗼𝗻𝗲 𝗯𝗲𝗳𝗼𝗿𝗲, 𝗮𝗻𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 External controls are not a novelty invented for this drug. Over the past two decades they have factored into roughly forty-five drug approvals by the United States regulator, each granted under the conditions that apply here: a serious or rare disease, a placebo that would be unethical, and high unmet need. Regulators do not grant this lightly. They grant it when the disease is serious, its course is predictable and objectively measured, and the effect is large. Glioblastoma meets all three. The named cases cover every part of this disease's profile. Defibrotide, for a life-threatening transplant complication, was approved on a propensity-score comparison to a historical control, the same kind of method used here. Blinatumomab, for an aggressive relapsed leukemia, is the precedent for a fast-killing cancer, cleared by both the United States and European regulators. Cerliponase alfa is the precedent for a fatal brain disease, cleared by both agencies on treated patients versus a matched natural-history group. Glioblastoma is both at once, a fast-killing cancer of the brain, read by the same method, so no part of its profile lacks a close approved precedent. And on the one axis that governs how far an external-control result can be trusted, DCVax-L goes beyond all three. Each of those drugs was tested in a single-arm trial, with no randomization at all. DCVax-L began as a randomized trial and became an external-control comparison only when ethics consumed its placebo group. It sits in that tradition, and at the top of it. 🎯 𝗧𝗵𝗲 𝗯𝗼𝘁𝘁𝗼𝗺 𝗹𝗶𝗻𝗲 This began as a randomized trial. Medical ethics forced it into an external-control comparison. Every independent way of checking it, on different data and different math, points the same direction, and the biology predicted that direction in advance. The first analysis did not overstate the vaccine's effect. Read with the right tools, it understated it.

Andrew Caravello, DO

11,406 görüntüleme • 2 ay önce